Kyntra Bio Financials - Benzinga

Kyntra Bio Inc

KYNBNASDAQ

Trade with Public

Trade with Public

$7.20

At close: Sep 22, 5:00 PM EST

$7.43

0.233.17%

After Hours: Sep 18, 8:49 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Kyntra Bio Financials

Kyntra Bio (KYNB) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
UPDATE: Kyntra Bio Q2 Adj. EPS $(4.68) Misses $(3.18) Estimate, Sales $(1.474M) Miss $2.007M Estimate

Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(4.68) per share which missed the analyst consensus estimate of $(3.18) by 47.17 percent. This is a 148.94 percent decrease over losses of $(1.88) per share from

Benzinga Newsdesk

PRO
Kyntra Bio Q2 EPS $2.96, Sales $(1.474M) Miss $2.007M Estimate

Benzinga Newsdesk

PRO
Kyntra Bio Q1 EPS $(3.76) Down From $1.15 YoY, Sales $3.738M Up From $2.739M YoY

Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.76) per share. This is a 426.96 percent decrease over earnings of $1.15 per share from the same period last year. The company reported $3.738 million in sales

Benzinga Newsdesk

Earnings Scheduled For May 11, 2026

Benzinga Insights

PRO
Kyntra Bio Q4 EPS $(3.61) Beats $(3.71) Estimate, Sales $1.300M Miss $1.425M Estimate

Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.61) per share which beat the analyst consensus estimate of $(3.71) by 2.56 percent. This is a 80.5 percent decrease over losses of $(2.00) per share from the same

Benzinga Newsdesk

Earnings Scheduled For March 16, 2026

Benzinga Insights